Skip to main content
Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · IEX Real-Time Price · USD
1.170
+0.020 (1.74%)
Jul 19, 2024, 4:00 PM EDT - Market closed

Virax Biolabs Group Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.
Year Ending
 CurrentMar 31, 2023
Market Capitalization
38
Enterprise Value
-2-1
PE Ratio
--1.49
PS Ratio
34.85947.36
PB Ratio
0.440.89
P/FCF Ratio
-0.84-1.86
P/OCF Ratio
-0.95-1.94
EV/Sales Ratio
1.60-128.02
EV/EBITDA Ratio
-0.20
EV/EBIT Ratio
-0.020.20
EV/FCF Ratio
-0.020.25
Debt / Equity Ratio
0.030.02
Debt / EBITDA Ratio
--0.03
Debt / FCF Ratio
-0.03-0.03
Quick Ratio
6.4910.30
Current Ratio
7.5910.61
Asset Turnover
0.010.00
Interest Coverage
-432.43-351.82
Return on Equity (ROE)
-129.10%-133.90%
Return on Assets (ROA)
-112.40%-110.70%
Return on Capital (ROIC)
-107.42%-61.82%
Earnings Yield
-250.54%-67.29%
FCF Yield
-218.90%-53.74%
Buyback Yield / Dilution
-664.03%-11.15%
Total Shareholder Return
-664.03%-11.15%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).